T1	Outcomes 58 74	serum bile acids
T2	Outcomes 302 314	tolerability
T3	Outcomes 326 346	bile acid metabolism
T4	Outcomes 830 847	study, bile acids
T5	Outcomes 862 973	by HPLC-MS in plasma and faeces, and fibroblast growth factor 19 (FGF19) and 7α-hydroxy-4-cholesten-3-one (C4)
T6	Outcomes 999 1032	RESULTS No serious adverse events
T7	Outcomes 1138 1178	study, plasma total bile acids and FGF19
T8	Outcomes 1303 1316	(P < 0.05).
T9	Outcomes 1317 1342	Plasma C4 and faecal bile
T10	Outcomes 1528 1546	majority of faecal
T11	Outcomes 1709 1749	interrupts the enterohepatic circulation
